...
首页> 外文期刊>Clinical & developmental immunology. >A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma
【24h】

A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma

机译:基于新型炎症的预后评分:纤维蛋白原/白蛋白比预测肝细胞癌治疗切除后患者的预期

获取原文

摘要

Background Inflammation is an important hallmark of cancer. Fibrinogen and albumin are both vital factors in systemic inflammation. This study investigated the prognostic value of the fibrinogen/albumin ratio in HCC patients who underwent curative resection. Methods HCC patients ( n = 151) who underwent curative resection were evaluated retrospectively. The optimal cutoff value for the fibrinogen/albumin ratio was selected by receiver operating characteristic (ROC) curve analysis. Correlations between preoperative fibrinogen/albumin ratios and clinicopathologic characteristics were analyzed by χ ~(2) test. The area under the receiver operating characteristic curve (AUC) was calculated to compare the prognostic value of the fibrinogen/albumin ratio with other prognostic scores (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and albumin-bilirubin (ALBI) score). The overall survival (OS) and time to recurrence (TTR) were assessed by the log-rank test and the Cox proportional hazard regression model. Results An optimal cutoff value of the preoperative fibrinogen/albumin ratio (0.062) was determined for 151 patients who underwent curative resection for HCC via a ROC curve analysis. Fibrinogen/albumin ratio?>?0.062 was significantly associated with microvascular invasion, an advanced BCLC stage, and ALBI grade. Multivariate analyses revealed that fibrinogen/albumin ratio was an independent predictor for OS ( P = 0.003) and TTR ( P = 0.035). The prognostic ability of fibrinogen/albumin ratio was comparable to other prognostic scores (NLR, PLR, and ALBI score) by AUC analysis. Patients with a fibrinogen/albumin ratio?>?0.062 had lower 1-, 3-, and 5-year OS rates (66.0%, 41.8%, and 28.2% versus 81.9%, 69.3%, and 56.1%, resp., P < 0.001) and higher 1-, 3-, and 5-year recurrence rates (60.9%, 79.2%, and 90.5% versus 49.5%, 69.1%, and 77.1%, resp., P = 0.008) compared with patients with fibrinogen/albumin ratio?≤?0.062. Conclusion The preoperative fibrinogen/albumin ratio is an effective prognostic factor for HCC patients who underwent curative resection. An elevated fibrinogen/albumin ratio significantly correlates with poorer survival and a higher risk of recurrence in HCC patients.
机译:背景炎症是癌症的重要标志。纤维蛋白原和白蛋白是全身炎症中的重要因素。本研究研究了HCC患者的纤维蛋白原/白蛋白比治疗治疗切除术的预后值。方法回顾性地评估接受治疗切除的HCC患者(N = 151)。通过接收器操作特性(ROC)曲线分析选择纤维蛋白原/白蛋白比的最佳截止值。通过χ〜(2)试验分析了术前纤维蛋白原/白蛋白比和临床病理特性之间的相关性。计算接收器操作特征曲线(AUC)的区域以比较纤维蛋白原/白蛋白与其他预后分数的预后值(中性粒细胞与淋巴细胞比(NLR),血小板至淋巴细胞比(PLR)和白蛋白 - 胆红素( Albi)得分)。通过对数秩检验和COX比例危险回归模型评估总存活(OS)和复发时间(TTR)。结果测定了术前纤维蛋白原/白蛋白比(0.062)的最佳截止值(0.062),通过ROC曲线分析处理HCC治疗疗法的151名患者。纤维蛋白原/白蛋白比例?> 0.062与微血管侵袭,先进的BCLC阶段和阿尔比等级显着相关。多变量分析显示,纤维蛋白原/白蛋白比是OS的独立预测因子(P = 0.003)和TTR(P = 0.035)。纤维蛋白原/白蛋白比的预后能力与AUC分析的其他预后评分(NLR,PLR和ALAMI评分)相当。纤维蛋白原/白蛋白比率的患者Δε?0.062较低的1-,3-和5年的OS率(66.0%,41.8%,28.2%,而81.9%,69.3%和56.1%,pres,p与纤维蛋白原患者相比,<0.001)和更高的1-,3-和5年的复发率(60.9%,79.2%和90.5%,69.1%和77.1%,p = 0.008) /白蛋白比率?≤≤0.062。结论术前纤维蛋白原/白蛋白比是患有治疗切除患者的HCC患者的有效预后因素。纤维蛋白原/白蛋白比升高与HCC患者的较差的存活率和更高的复发风险显着相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号